Skip to main content
. 2018 Feb 9;9(17):13733–13747. doi: 10.18632/oncotarget.24460

Figure 3. IHC analysis of RG, TCL, the RG and the TCL derived tumors.

Figure 3

(A1) ps62cMYC 10x (LC26-RTL(170) 12 weeks post-injection) - expression is observed in over 25% of tumor cells, (A2) cMYC 40x (LCAS-RTL(138) 9 weeks post-injection) - expression is observed in over 25% of tumor cells, (A3) EPHA3 5x (LC25-R 8 weeks post-injection) - extensive expression is observed in tumor cells, (A4) EPHA3 63x (LCAS-R 12 weeks post-injection) - perivascular invading tumor cells show overexpression of EPHA3, (B1, B2) p53 40x (LCAS-R/LCAS-RTL(138)) - B1: show low expression of p53 (<10%) while B2 show over 75% of p53 expressing cells, (B3, B4) p53 40x (LC26-R/LC26-RTL(170)) - B3: show low expression of p53 (<20%) while B4 show over 60% of p53 expressing cells, (C1, C2) p53 20x, 40x (LCAS-RTL(138) 15 weeks post-injection) - approximately 45% of tumor cells show expression of p53, (C3, C4) p53 20x, 40x (LC26-RTL(170) 12 weeks post-injection) - approximately 45% of tumor cells show expression of p53. (D1, D2) MDM2 20x, 40x (LCAS-RTL(138) 15 weeks post-injection) - approximately 50% of tumor cells show expression of p53, (D3, D4) MDM2 20x, 40x (LC26-RTL(170) 12 weeks post-injection) - approximately 50% of tumor cells show expression of p53. TU-tumor; P-parenchyma; V-ventricle; PI- perivascular invasion.